Rapid review finds molnupiravir, nirmatrelvir–ritonavir, and simnotrelvir–ritonavir increased recovery or reduced time to recovery with varying adverse event profiles, and molnupiravir could have long-term benefits for 3 to 6 months.
While shorter time to blood culture positivity was linked with infective endocarditis, it was not associated with mortality or sepsis in Streptococcus agalactiae bacteremia.
Researchers evaluated perioperative and postdischarge factors associated with opioid refill prescriptions during the first 90 days after inpatient otolaryngology–head and neck surgery.
A UK quality improvement project reports wide variation in emissions and wastage from nitrous oxide sedation, highlighting opportunities to reduce environmental harm while maintaining patient care.